69 related articles for article (PubMed ID: 27323039)
1. Analysis of regulatory mechanism after ErbB4 gene mutation based on local modeling methodology.
Chen CL; Zhao JW
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323039
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Wandinger SK; Lahortiga I; Jacobs K; Klammer M; Jordan N; Elschenbroich S; Parade M; Jacoby E; Linders JT; Brehmer D; Cools J; Daub H
PLoS One; 2016; 11(1):e0146100. PubMed ID: 26745281
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy.
Sahu A; Patra PK; Yadav MK; Varma M
J Recept Signal Transduct Res; 2017 Oct; 37(5):470-480. PubMed ID: 28670936
[TBL] [Abstract][Full Text] [Related]
4. Activating ERBB4 mutations in non-small cell lung cancer.
Kurppa KJ; Denessiouk K; Johnson MS; Elenius K
Oncogene; 2016 Mar; 35(10):1283-91. PubMed ID: 26050618
[TBL] [Abstract][Full Text] [Related]
5. ErbB4 point mutation in CU3 inbred rats affects gonadotropin-releasing-hormone neuronal function via compromised neuregulin-stimulated prostaglandin E2 release from astrocytes.
Moeller-Gnangra H; Ernst J; Pfeifer M; Heger S
Glia; 2019 Feb; 67(2):309-320. PubMed ID: 30485552
[TBL] [Abstract][Full Text] [Related]
6. The role of ErbB4 in cancer.
Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
[TBL] [Abstract][Full Text] [Related]
7. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
8. Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation.
Haryuni RD; Watabe S; Yamaguchi A; Fukushi Y; Tanaka T; Kawasaki Y; Zhou Y; Yokoyama S; Sakurai H
Biochem Biophys Res Commun; 2019 Jun; 514(2):456-461. PubMed ID: 31053301
[TBL] [Abstract][Full Text] [Related]
9. Neuregulin 1-activated ERBB4 as a "dedicated" receptor for the Hippo-YAP pathway.
Sudol M
Sci Signal; 2014 Dec; 7(355):pe29. PubMed ID: 25492964
[TBL] [Abstract][Full Text] [Related]
10. Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake.
Haskins JW; Zhang S; Means RE; Kelleher JK; Cline GW; Canfrán-Duque A; Suárez Y; Stern DF
Sci Signal; 2015 Nov; 8(401):ra111. PubMed ID: 26535009
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations of the ERBB4 kinase domain in human cancers.
Soung YH; Lee JW; Kim SY; Wang YP; Jo KH; Moon SW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
Int J Cancer; 2006 Mar; 118(6):1426-9. PubMed ID: 16187281
[TBL] [Abstract][Full Text] [Related]
12. Cbl and Itch binding sites in ERBB4 CYT-1 and CYT-2 mediate K48- and K63-polyubiquitination, respectively.
Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2013 Feb; 25(2):470-8. PubMed ID: 23153581
[TBL] [Abstract][Full Text] [Related]
13. Phosphotyrosine interactome of the ErbB-receptor kinase family.
Schulze WX; Deng L; Mann M
Mol Syst Biol; 2005; 1():2005.0008. PubMed ID: 16729043
[TBL] [Abstract][Full Text] [Related]
14. Ligand-independent regulation of ErbB4 receptor phosphorylation by activated Ras.
Tal-Or P; Erlich S; Porat-Shliom N; Goldshmit Y; Ben-Baruch G; Shaharabani E; Kloog Y; Pinkas-Kramarski R
J Cell Biochem; 2006 Aug; 98(6):1482-94. PubMed ID: 16518842
[TBL] [Abstract][Full Text] [Related]
15. Trophoblast subtype-specific EGFR/ERBB4 expression correlates with cell cycle progression and hyperplasia in complete hydatidiform moles.
Fock V; Plessl K; Fuchs R; Dekan S; Milla SK; Haider S; Fiala C; Knöfler M; Pollheimer J
Hum Reprod; 2015 Apr; 30(4):789-99. PubMed ID: 25740878
[TBL] [Abstract][Full Text] [Related]
16. Structural and thermodynamic insight into the process of "weak" dimerization of the ErbB4 transmembrane domain by solution NMR.
Bocharov EV; Mineev KS; Goncharuk MV; Arseniev AS
Biochim Biophys Acta; 2012 Sep; 1818(9):2158-70. PubMed ID: 22579757
[TBL] [Abstract][Full Text] [Related]
17. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.
Naresh A; Long W; Vidal GA; Wimley WC; Marrero L; Sartor CI; Tovey S; Cooke TG; Bartlett JM; Jones FE
Cancer Res; 2006 Jun; 66(12):6412-20. PubMed ID: 16778220
[TBL] [Abstract][Full Text] [Related]
18. Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3'-untranslated region of ErbB4 in breast cancer.
Bagheri F; Mesrian Tanha H; Mojtabavi Naeini M; Ghaedi K; Azadeh M
Mol Med Rep; 2016 May; 13(5):4494-8. PubMed ID: 27035115
[TBL] [Abstract][Full Text] [Related]
19. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.
Williams CC; Allison JG; Vidal GA; Burow ME; Beckman BS; Marrero L; Jones FE
J Cell Biol; 2004 Nov; 167(3):469-78. PubMed ID: 15534001
[TBL] [Abstract][Full Text] [Related]
20. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
